Emcure Pharmaceuticals

What Emcure Pharmaceuticals does

Emcure Pharmaceuticals Limited is a publicly-listed Indian pharmaceutical manufacturer headquartered in Pune, Maharashtra, that develops, manufactures, and globally markets a broad portfolio of pharmaceutical products across gynaecology, cardiovascular, anti-infectives, vitamins/minerals/nutrients, HIV antivirals, anti-diabetics, oncology, and obesity/metabolic health. Founded in 1981 by Satish Mehta and listed on NSE and BSE since July 2024, Emcure operates through wholly-owned subsidiaries including Gennova Biopharmaceuticals (mRNA vaccines, biosimilars, tenecteplase, erythropoietin, filgrastim, pegaspargase), Zuventus Healthcare (domestic distribution), Tillomed Laboratories (UK/Europe), Marcan Pharmaceuticals and Mantra Pharma (Canada), Emcure Pharma South Africa, plus Latin American, Middle Eastern, and Asia-Pacific offices covering 70+ countries.

The company's technology base spans vertical integration from active pharmaceutical ingredient (API) manufacturing through finished formulations, with proprietary platforms in liposomal drug delivery, long-acting injectables, nasal delivery, self-amplifying mRNA, chirality (including S-Amlodipine), peptide APIs, iron-based formulations, and perfusion-based mammalian bioreactor systems for biologics. Emcure has 234 patents filed globally with 201 approved, runs five R&D centers including the 2025-opened Emcure Research Centre in Ahmedabad, and operates 13 advanced manufacturing facilities across India. Flagship branded products include Elaxim/TENECTASE (tenecteplase), Vintor (erythropoietin), Xgrast (filgrastim), Hamsyl (pegaspargase), GEMCOVAC-19, and GEMCOVAC-OM, alongside exclusive distribution of Novo Nordisk's semaglutide under the Poviztra brand and Roche's nephrology portfolio from April 2026.

Emcure's revenue model combines direct sales forces and wholly-owned subsidiaries for domestic India (44% of FY26 revenue) and regulated international markets (Europe, Canada), with local distributors in emerging markets. International business contributed 56% of FY26 revenue at Rs 5,177 crore (up 22.2% YoY), bringing total revenue to Rs 9,204 crore (approximately $1 billion), with net profit of Rs 941 crore (+33.1% YoY) and Return on Capital Employed of 23.7%. Customer reach extends across hospitals, pharmacies, clinics, and end patients, with celebrity-led direct-to-consumer marketing for consumer-facing products like Poviztra and traditional physician outreach across the broader portfolio.

Name

Emcure Pharmaceuticals

Legal name

Emcure Pharmaceuticals Limited

Website

https://emcure.com

Company type

Public

Founded year

1981

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Emcure Pharmaceuticals is an Indian-listed pharmaceutical company that develops, manufactures, and globally markets generic formulations, biosimilars, APIs, and mRNA vaccines across gynaecology, cardiovascular, oncology, HIV, and metabolic health, serving patients and healthcare providers in 70+ countries through its own subsidiaries and distribution network.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Generic pharmaceuticals manufacturing
• Biologics and biosimilars
• Active pharmaceutical ingredients
• Liposomal drug delivery
• MRNA vaccine development

Headquarters

HQ city

Pune

HQ country

India

HQ region

Asia

Offices17 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Domestic India Sales: Revenue from pharmaceutical product sales in Indian domestic market across therapeutic areas including gynaecology, cardiovascular, anti-infectives, and women's health. Contributed 44% of FY26 revenue.
2. International/Export Sales: Revenue from pharmaceutical exports to regulated markets (Europe, Canada) and emerging markets. Grew 22.2% to ₹5,177 crore, contributing 56% of FY26 revenue. Includes subsidiary operations in UK, Canada, South Africa, and other international markets.
3. Licensing and Distribution Partnerships: Revenue from exclusive distribution agreements with Novo Nordisk for Poviztra (semaglutide) and Roche for nephrology products. Also includes in-licensing arrangements with partners like Sanofi.
4. Biologics and Biosimilars: Revenue from Gennova Biopharmaceuticals subsidiary including products like Elaxim (tenecteplase), TENECTASE, Vintor (erythropoietin), and biosimilar pipeline including bevacizumab for wet AMD.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Emcure Pharmaceuticals manufactures and globally markets a broad range of pharmaceutical products across therapeutic areas including gynaecology, cardiovascular, anti-infectives, vitamins/minerals/nutrients, HIV antivirals, anti-diabetic, oncology/anti-neoplastics, and weight management. The portfolio spans orals, injectables, biotherapeutics/biosimilars, mRNA vaccines, and Active Pharmaceutical Ingredients (APIs), distributed across more than 70 countries. Emcure also exclusively distributes third-party products (Novo Nordisk's semaglutide, Roche's nephrology portfolio) in India.

Product overview

Emcure Pharmaceuticals is an Indian pharmaceutical company offering a diversified portfolio of pharmaceutical products across several therapeutic areas. The company operates through three main product categories: (1) Biologics/Biosimilars through its subsidiary Gennova Biopharmaceuticals, including GEMCOVAC mRNA vaccines, tenecteplase (Elaxim/TENECTASE), erythropoietin (Vintor), filgrastim (Xgrast), PEG-filgrastim (PEGEX), and pegaspargase (Hamsyl/Hamsyl Junior); (2) Generic pharmaceutical formulations including orals, injectables, and complex drug delivery systems such as liposomal products, long-acting injectables, and modified-release formulations; (3) Active Pharmaceutical Ingredients (APIs) including antiretrovirals for HIV/AIDS, iron-based products, and chiral molecules. Emcure also distributes Novo Nordisk's semaglutide product (Poviztra) for obesity management in India. The company has a strong focus on differentiated products including first-to-market launches in gynaecology, cardiovascular, and biologics.

Differentiator

Problem solved

Functional benefit

Brands

• Poviztra: Semaglutide injection for weight management, distributed in partnership with Novo Nordisk
• Elaxim
• TENECTASE
• Vintor
• Xgrast
• Hamsyl

Products and services

• GEMCOVAC-19 India's first mRNA-based COVID-19 vaccine targeting the Wuhan strain, approved by CDSCO for emergency use; the world's first thermostable mRNA vaccine.
• GEMCOVAC-OM Omicron-specific mRNA COVID-19 vaccine approved by CDSCO for emergency use; the world's first thermostable mRNA vaccine against the Omicron variant.
• Elaxim (Tenecteplase) Biologic tenecteplase product for Acute Myocardial Infarction (AMI), available in 30mg, 40mg, and 52.5mg strengths. Launched in 2007.
• TENECTASE Biologic tenecteplase product for Acute Ischemic Stroke (AIS), 20mg strength. Launched in 2016; recognized by the Department of Biotechnology, Govt. of India for stroke treatment development.
• Vintor (Erythropoietin) Biologic erythropoietin for anemia due to Chronic Renal Failure (CRF), available in 2000 IU, 3000 IU, 4000 IU, 6000 IU, 10000 IU, and 20000 IU strengths.
• Xgrast (Filgrastim) Biologic filgrastim (G-CSF) for febrile neutropenia after chemotherapy in cancer patients, available in 150mcg, 300mcg, and 480mcg strengths. Launched in 2010.
• PEGEX (PEG-filgrastim) PEGylated filgrastim product for febrile neutropenia, available in 6mg/0.6ml strength.
• Hamsyl (Pegaspargase) Generic pegaspargase for acute lymphoblastic lymphoma (ALL), available in 3750 IU/5ml strength. Launched in 2014.
• Hamsyl Junior Pediatric pack size of pegaspargase for acute lymphoblastic lymphoma (ALL) in children, available in 1500 IU/2ml strength. Launched in 2024 — first-of-its-kind pediatric pack size in India.
• Poviztra (Semaglutide) Semaglutide injection for chronic weight management, available in five dosage strengths as a once-weekly pen device; distributed and commercialized in India under exclusive partnership with Novo Nordisk.
• Antiretroviral APIs (Atazanavir, Ritonavir, Tenofovir, Dolutegravir, Lenacapavir) Active Pharmaceutical Ingredients for HIV/AIDS treatment including Atazanavir, Ritonavir (commonly used as booster), Tenofovir (HIV/AIDS and hepatitis B), Dolutegravir, and Lenacapavir (obtained via voluntary license from Gilead for development).
• Iron-based APIs (Ferric Carboxy Maltose, Ferrous Ascorbate) Flagship iron-based APIs and products for anemia treatment, including Ferric Carboxy Maltose and Ferrous Ascorbate, in Emcure's portfolio.
• Liposomal Formulations (Amphotericin B, Doxorubicin) Liposomal drug delivery products using spherical microscopic phospholipid bilayer carriers for targeted delivery and controlled release — Amphotericin B (fungal infections) and Doxorubicin (cancer treatment).
• Long-Acting Injectables (Leuprolide, Propofol) Long-acting injectable formulations including Leuprolide (hormonal therapy for prostate cancer and other conditions) and Propofol (injectable emulsion for anesthesia), using polymer-based, oil-based, and crystalline drug suspension technologies for sustained and controlled release.
• Carmustine RTU Ready-to-use injectable carmustine formulation for cancer treatment.
• Modified-Release Formulations (Duloxetine MR, Propranolol MR) Modified-release oral formulations — Duloxetine MR for depression and anxiety, and Propranolol MR for cardiovascular conditions.
• S-Amlodipine (Chiral API/Product) Chiral S-enantiomer of Amlodipine Besylate for hypertension, produced using Emcure's asymmetric synthesis and chiral resolution chiral technology; offers enhanced therapeutic activity compared to the racemic mixture.
• Peptide APIs (Atosiban, Avaptidil) Peptide Active Pharmaceutical Ingredients produced using solution and solid phase peptide chemistry, including Atosiban and Avaptidil.
• Platinum-based Chemotherapy Drugs (Carboplatin, Cisplatin, Oxaliplatin) Platinum-based chemotherapy agents — carboplatin, cisplatin, and oxaliplatin — supplied to hospital and pharmacy networks across India for cancer treatment.
• Roche Nephrology Portfolio (CellCept, Mircera, Neorecormon) Exclusive distribution in India of Roche's nephrology and transplant medicine portfolio from April 2026: CellCept (immunosuppressant), Mircera (anemia), and Neorecormon for chronic kidney disease and transplant care.

Quantifiable outcome

• Revenue exceeded $1 billion milestone in FY26 with 16.6% growth
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Six partnerships are on record, tiered minor and core.

• Kotak Mahindra CapitalminorOthers · 25 June 2026Investment bank acted as adviser for Bain Capital's exit from Emcure through block deal
• Axis CapitalminorOthers · 25 June 2026Investment bank acted as adviser for Bain Capital's exit from Emcure through block deal
• SanofiminorChannel Partner/ Reseller/ Distributor · 5 May 2026Partnership with Sanofi for oral antidiabetic drugs as part of portfolio expansion strategy
• RochecoreChannel Partner/ Reseller/ Distributor · 2 March 2026Emcure signed distribution agreement with Roche to distribute select nephrology and transplant medicine portfolio in India from April 1, 2026. Agreement covers CellCept (immunosuppressant), Mircera (anemia treatment), and Neorecormon for chronic kidney disease and transplant care, aiming to expand patient access to these critical therapies.
• Novo NordiskcoreChannel Partner/ Reseller/ Distributor · 22 December 2025Emcure holds exclusive partnership with Novo Nordisk to market semaglutide injection under brand Poviztra in India. The company launched Poviztra at ₹8,790 per month, later reducing price by 55% to ₹3,999 per month following patent expiry and market competition. This partnership positions Emcure as the first Indian company to exclusively distribute Novo Nordisk's semaglutide injection for obesity.
• Sakar HealthcareminorOthers · 1 January 2025Technology transfer partnership mentioned in context of Sakar Healthcare's oncology business with major pharma companies including Emcure

Scale indicators25 records

Recent moves11 records

Expansion highlights7 records

Direct peers

• Torrent Pharmaceuticals: Mid-sized Indian pharma with comparable chronic-disease focus (cardiovascular, CNS, gastrointestinal) and similar international expansion trajectory into Latin America and other emerging markets.
• Zydus Lifesciences (Cadila Healthcare): Indian integrated pharma player with highly comparable activities: complex generics, biosimilars, APIs, and novel biologics. Overlapping therapeutic focus on cardiology, gynecology, and oncology with a similarly broad emerging markets footprint.
• Aurobindo Pharma: Indian pharma major with comparable API-to-formulation vertical integration, strong ARV portfolio overlap with Emcure, and similar export-led business model targeting the US and emerging markets.
• Biocon: Indian biopharmaceutical company with a comparable biosimilars and biologics platform (similar to Gennova). Direct overlap on biosimilars pipeline, contract manufacturing, and emerging markets biologics commercialization.
• Cipla: One of India's largest pharmaceutical companies with a comparable diversified portfolio spanning respiratory, cardiovascular, anti-infectives, and biosimilars. Both companies serve Indian and international markets with branded generics, complex formulations, and a strong presence in emerging markets.
• Glenmark Pharmaceuticals: Indian pharma with overlapping specialty formulations portfolio, complex generics focus, and emerging markets distribution. Direct competitor in cardiovascular, dermatology, and respiratory segments.
• Dr. Reddy's Laboratories: Indian pharma major with overlapping focus on complex generics, biosimilars, and proprietary products. Comparable in API-to-formulation vertical integration, US generics presence, and emerging markets footprint across cardiovascular, oncology, and specialty therapy areas.
• Lupin: Indian pharma with a directly comparable diversified portfolio in cardiovascular, anti-infectives, women's health, and complex generics. Both companies have strong R&D platforms targeting US ANDA approvals and biosimilar development.

Broad incumbents

• Sun Pharmaceutical Industries: India's largest pharmaceutical company with a far broader portfolio including specialty, generics, and branded formulations. Comparable in chronic-disease focus, complex generics, and US/emerging market distribution, but at materially greater scale and brand recognition.

Emerging players

• Natco Pharma: Indian pharma with overlapping oncology and API focus. Comparable niche in complex generics and specialty injectables, but at smaller scale and narrower therapeutic scope than Emcure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/EmcurePharma
• YouTubeyoutube.com/@UnconditionYourself/videos
• Facebookfacebook.com/emcurepharmaofficial
• LinkedInin.linkedin.com/company/emcure-pharmaceuticals-limited
• Instagraminstagram.com/emcurepharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emcure Pharmaceuticals